Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial.

Trial Profile

Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms GastroLap
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2016 Discrepancy in status. NCT reports as discontinued, Eudra reports as suspended and German Clinical Trial Register reports as active, no longer recruiting. Retained it as per NCT, as it is a reliable source.
    • 24 Apr 2013 Planned end date changed from 1 Jul 2015 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top